Sudarshan Pharma Industries (543828) Q3 25/26 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December 2025 were approved and reviewed by the Board and auditors, with no material misstatements noted.

Financial highlights

• Standalone revenue from operations for Q3 FY26 was ₹15,837.13 lakhs, with net profit at ₹430.54 lakhs, up from ₹275.82 lakhs in Q3 FY25.

• Consolidated revenue for Q3 FY26 was ₹16,800.66 lakhs, with net profit at ₹414.85 lakhs, compared to ₹288.20 lakhs in Q3 FY25.

• Nine-month standalone net profit reached ₹1,243.89 lakhs, and consolidated net profit was ₹1,197.93 lakhs.

• Basic and diluted EPS for Q3 FY26 stood at ₹0.18 (standalone) and ₹0.18 (consolidated).

Outlook and guidance

• The company voluntarily adopted Ind AS from April 1, 2025, with restated prior period figures for comparability.